News
Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of ...
Cruz, J, Reis-Filho, JS, Silva, P, Lopes, JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003;65:72-82 ...
FGFR Drug Market To Surpass USD 4 Billion By 2026 Says Kuick ResearchDelhi, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and ...
Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ...
Focal amplifications of genes within the receptor tyrosine kinase–Ras–phosphoinositide 3-kinase signaling pathway were found in 47% of DIPGs, the most common of which involved PDGFRA and MET. Thirty ...
SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF and PDGF receptors, ... a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer . Next. Figures Tables. Close ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results